OmniaBio Inc., a subsidiary of Toronto-based CCRM, is a contract development and manufacturing organization (CDMO) producing gene-modified cell therapies and viral vectors, compliant with Good Manufacturing Practices (cGMP) standards. At approximately 245,000 ft2 (23,225 m2) in phase one (all of Building B – 80,000 ft2 – plus a portion of Building A – 165,000 ft2) with plans to reach 400,000 ft2 (37,161 m2) when Building A is completed, OmniaBio will be the largest facility of its kind in Canada.
OmniaBio will be the anchor tenant in a biomanufacturing centre of excellence at McMaster Innovation Park in Hamilton, Ontario. It is expected to catalyze life sciences jobs and innovation in Ontario while advancing pioneering medicine with the potential to cure, not just treat, many forms of cancer, cardiovascular diseases, Parkinson’s and diabetes.
OmniaBio will support a broad range of cell and gene therapy companies from Canada and internationally, and tap into a global demand for cell and gene therapy manufacturing that outstrips supply by at least five times. By providing commercial-scale manufacturing in Ontario, cell and gene companies across Canada will be able to commercialize their therapies domestically, ensuring that Canada retains the intellectual property, technical know-how and talent.
OmniaBio will complete CCRM’s continuum of process development, clinical and commercial capabilities, building on the work that takes place at CCRM’s Centre for Cell and Vector Production (CCVP) located at the MaRS Centre in Toronto’s Discovery District. CCVP is a cGMP-compliant facility for Phase I/II in-human clinical trials. OmniaBio will enable pivotal/Phase III and commercial-scale manufacturing for cell and gene therapies.
To read about OmniaBio’s initial funding support from the Government of Ontario, please visit our news page.
To read about OmniaBio’s private investor, read our news release here.
To reach us, please visit the Contact Us page.